Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,127 stopped studies mapped to Secondary Malignant Neoplasm and descendants · 91% state a reason
Over the 2,127 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04402788 | Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment… | Phase 2 / Phase 3 | suspended | May 27, 2020 | National Cancer Institute (NCI) | Scheduled Interim Monitoring | Other (stated, no rule matched) |
| NCT05691478 | A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With… | Phase 2 / Phase 3 | suspended | Jan 20, 2023 | National Cancer Institute (NCI) | Other - Extend the observation period for current patients | Other (stated, no rule matched) |
| NCT06505018 | Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients…(ALTERNATIVE) | N/A | terminated | Jul 17, 2024 | UNICANCER | The study was terminated prematurely due to insufficient patient recruitment. | Enrollment / accrual |
| NCT03494569 | Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell… | Phase 1 | suspended | Apr 11, 2018 | City of Hope Medical Center | Accrual goal | Enrollment / accrual |
| NCT03833167 | Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants… | Phase 3 | terminated | Feb 6, 2019 | Merck Sharp & Dohme LLC | The study stopped due to futility | Efficacy / futility |
| NCT04570956 | Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular… | Phase 2 | terminated | Sep 30, 2020 | Mayo Clinic | grant and funding expired | Funding |
| NCT04844073 | A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer | Phase 1 / Phase 2 | terminated | Apr 14, 2021 | Takeda | Sponsor decision based on limited anti-cancer activity of TAK-186. | Sponsor / business decision |
| NCT05575440 | Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer | — | terminated | Oct 12, 2022 | Mayo Clinic | Slow accrual; lack of eligible study participants | Enrollment / accrual |
| NCT06882746 | A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon,… | Phase 1 | terminated | Mar 19, 2025 | Boehringer Ingelheim | Sponsor decision | Sponsor / business decision |
| NCT04638751 | ARGONAUT: Stool and Blood Sample Bank for Cancer Patients | — | suspended | Nov 20, 2020 | Persephone Biosciences | Currently no funding to continue study. | Funding |
| NCT05316688 | A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell… | Phase 1 / Phase 2 | terminated | Apr 7, 2022 | University of Washington | Terminated due to suboptimal delineation of fluorescence between tumor and native oral cavity… | Other (stated, no rule matched) |
| NCT04286386 | Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam | — | withdrawn | Feb 27, 2020 | M.D. Anderson Cancer Center | No Participants Enrolled | Enrollment / accrual |
| NCT05378464 | Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab… | Phase 1 | suspended | May 18, 2022 | H. Lee Moffitt Cancer Center and Research Institute | Wait for the DLT period with our current patient and will not be enrolling any more. | Enrollment / accrual |
| NCT05908786 | A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in… | Phase 1 / Phase 2 | terminated | Jun 18, 2023 | Hoffmann-La Roche | Study was closed early as the sponsor decided not to continue development of certain treatment… | Sponsor / business decision |
| NCT06968195 | Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or… | Phase 1 | suspended | May 13, 2025 | Roswell Park Cancer Institute | awaiting agreement with Sponsor | Other (stated, no rule matched) |
| NCT03077841 | Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast… | Phase 2 / Phase 3 | suspended | Mar 13, 2017 | M.D. Anderson Cancer Center | PI Requested | Other (stated, no rule matched) |
| NCT04111172 | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma | Phase 2 | suspended | Oct 1, 2019 | Thomas Jefferson University | Protocol is with FDA review, waiting for funding to be released | Funding |
| NCT04191135 | Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After… | Phase 2 | terminated | Dec 9, 2019 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT05403723 | Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC | Phase 1 | suspended | Jun 3, 2022 | University of Maryland, Baltimore | PI changed institution. Not yet approved at current location. | Other (stated, no rule matched) |
| NCT06722807 | ClAmpless, Sutureless PartIAl Nephrectomy for Renal Masses(CASPIAN) | N/A | suspended | Dec 9, 2024 | University of Florida | Interim analysis | Efficacy / futility |
| NCT07365839 | Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular…(CLeAR) | Phase 1 | withdrawn | Jan 26, 2026 | Virginia Commonwealth University | The study was withdrawn because the pharmaceutical company decided not to pursue this combination… | Sponsor / business decision |
| NCT01039922 | SwissNET - a Registry for Neuroendocrine Tumours in Switzerland(SwissNET) | — | terminated | Dec 25, 2009 | Insel Gruppe AG, University Hospital Bern | The register will no longer be maintained on a prospective basis | Other (stated, no rule matched) |
| NCT07181720 | CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors | Phase 1 | suspended | Sep 18, 2025 | Chongqing Precision Biotech Co., Ltd | Sponsor stopped the study. | Other (stated, no rule matched) |
| NCT04251533 | Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With…(EPIK-B3) | Phase 3 | terminated | Feb 5, 2020 | Novartis Pharmaceuticals | The study was terminated following a strategic decision to halt recruitment due to persistently… | Safety / toxicity |
| NCT05111626 | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for…(FORTITUDE-102) | Phase 3 | terminated | Nov 8, 2021 | Amgen | Study was terminated by sponsor | Other (stated, no rule matched) |
| NCT05685602 | CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic… | Phase 1 | suspended | Jan 17, 2023 | National Cancer Institute (NCI) | Drug Supply Issues | Drug supply |
| NCT03145857 | A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors… | Phase 1 / Phase 2 | terminated | May 9, 2017 | AHS Cancer Control Alberta | The market approved 68Ga-DOTATATE (NETSPOT(R)) is now approved for public funding in Alberta and is… | Drug supply |
| NCT04246177 | Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in… | Phase 3 | terminated | Jan 29, 2020 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT06671912 | Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial(LoTam) | Phase 3 | suspended | Nov 4, 2024 | Alliance for Clinical Trials in Oncology | Amending protocol to increase sample size | Other (stated, no rule matched) |
| NCT06790966 | Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck…(VERSATILE-003) | Phase 3 | terminated | Jan 24, 2025 | PDS Biotechnology Corp. | The study is being discontinued solely based on financial constraints and is not related to the… | Safety / toxicity |
| NCT06929338 | xDRIVE in Metastatic Colorectal Cancer | — | withdrawn | Apr 16, 2025 | First Ascent Biomedical Inc. | Unable to finalize study agreements | Other (stated, no rule matched) |
| NCT01810913 | Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to… | Phase 2 / Phase 3 | suspended | Mar 14, 2013 | National Cancer Institute (NCI) | Other - Assessing accrual feasibility | Enrollment / accrual |
| NCT06568172 | Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the… | Phase 3 | suspended | Aug 23, 2024 | National Cancer Institute (NCI) | Other - Other | Other (stated, no rule matched) |
| NCT05756166 | Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of… | Phase 1 / Phase 2 | terminated | Mar 6, 2023 | Roswell Park Cancer Institute | Funding ended | Funding |
| NCT06990737 | Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically… | Phase 2 | withdrawn | May 25, 2025 | University of California, Davis | Poor accrual | Enrollment / accrual |
| NCT07042295 | Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in… | Phase 2 | suspended | Jun 29, 2025 | National Cancer Institute (NCI) | Other - planned analysis of safety and efficacy data | Safety / toxicity |
| NCT06982222 | Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have… | Phase 1 | withdrawn | May 21, 2025 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT04669860 | Evaluating the Bacterial and Fungal Microbiome in Patients With Calcium Oxalate… | — | suspended | Dec 17, 2020 | University of Miami | lack of funding | Funding |
| NCT02993068 | Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) | N/A | suspended | Dec 14, 2016 | M.D. Anderson Cancer Center | Accrual Limit | Enrollment / accrual |
| NCT03442556 | Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic… | Phase 2 | terminated | Feb 22, 2018 | University of Washington | Terminated due to insufficient funding | Funding |
| NCT01216371 | Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant…(SMAT) | Phase 2 | terminated | Oct 7, 2010 | Association of Urologic Oncology (AUO) | not stated | Not stated |
| NCT04601428 | Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC) | Early Phase 1 | terminated | Oct 23, 2020 | Koo Foundation Sun Yat-Sen Cancer Center | The decision has been made to terminate the study due to logistical reasons and not due to any… | Safety / toxicity |
| NCT04019327 | A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer | Phase 1 / Phase 2 | terminated | Jul 15, 2019 | Memorial Sloan Kettering Cancer Center | Study terminated by sponsor | Other (stated, no rule matched) |
| NCT05780879 | A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission… | Phase 2 | terminated | Mar 23, 2023 | University of Michigan Rogel Cancer Center | Interim Analysis per Protocol | Efficacy / futility |
| NCT06620302 | Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment… | Phase 1 / Phase 2 | suspended | Oct 1, 2024 | Children's Oncology Group | Unacceptable Toxicity | Safety / toxicity |
| NCT04949256 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus… | Phase 3 | terminated | Jul 2, 2021 | Merck Sharp & Dohme LLC | Trial was rendered as cancelled work ongoing in the book of business. | Sponsor / business decision |
| NCT06250036 | Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer(ZODIAC) | Phase 2 | suspended | Feb 8, 2024 | Royal Marsden NHS Foundation Trust | Gilead's ongoing evaluation of the wider Zimberelimab and Domvanalimab programme, following the… | Safety / toxicity |
| NCT03274258 | Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma | Phase 2 | terminated | Sep 6, 2017 | M.D. Anderson Cancer Center | The study met its prespecified futility criteria during the prespecified interim futility analysis… | Efficacy / futility |
| NCT04473781 | Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer | Phase 1 | terminated | Jul 16, 2020 | Jonsson Comprehensive Cancer Center | slow Accrual | Enrollment / accrual |
| NCT05724602 | Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck…(RAVINA) | Phase 2 | terminated | Feb 13, 2023 | European Organisation for Research and Treatment of Cancer - EORTC | discontinuation of all ongoing studies involving xevinapant | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 11 hours agoSource updated Sep 29, 2026source: clinicaltrials